Alzheimer's and Dementia: Translational Research and Clinical Interventions
Publisher: Wiley · ISSN 23528737 · 20 articles
- Replication and colocalization refine gene prioritization in vascular dementia
-
Atomoxetine and risk of Alzheimer's disease in older adults
Abstract INTRODUCTION Experimental studies and a previous small, randomized trial suggest that atomoxetine, a selective norepinephrine reuptake inhibitor, may be efficacious in the prevention or disease modification of Alzheimer's...
-
Statistical efficiency of outcome measures for secondary prevention trials in Alzheimer's disease: Evidence from the A4 trial
Abstract INTRODUCTION Secondary prevention trials targeting preclinical Alzheimer's disease (AD) require clinical outcome assessments (COAs) that are sensitive to subtle decline that might be found in the cognitively unimpaired...
-
Comparative functional and cognitive trajectories following second‐generation antipsychotic initiation among long‐term care residents with Alzheimer disease: A target trial emulation study
Abstract Introduction Real‐world evidence comparing the functional and cognitive outcomes associated with commonly prescribed second‐generation antipsychotics (SGAs) in long‐term care (LTC) residents with Alzheimer disease (AD) is...
- Translating exploratory findings to targeted music‐based trials in dementia: Response to comments by Liu & Xu
- Aligning components, context, and endpoints in music‐based dementia trials
-
Efficacy of ORM‐12741 on agitation/aggression symptoms in participants with Alzheimer's disease
Abstract INTRODUCTION ORM‐12741 is a potent and selective alpha‐2C adrenoceptor antagonist. The primary objective of this study was to evaluate the efficacy of ORM‐12741 in treating agitation/aggression symptoms in patients with...
-
Communication and shared decision‐making for anti‐amyloid therapy in early Alzheimer's disease: An exploratory qualitative study of real‐world audio‐recorded clinical encounters
Abstract INTRODUCTION Anti‐amyloid therapies (AATs) for Alzheimer's disease (AD) offer modest slowing of cognitive decline but involve meaningful risks, burdens, and uncertainty. Decisions about AAT are preference sensitive and...
-
Combined administration of buntanetap and dulaglutide counteracts synaptic dysfunction and memory loss in an Alzheimer's disease mouse model
Abstract INTRODUCTION Alzheimer's disease (AD) results from disruptions in proteostasis, metabolism, and neurotrophic signaling that impair synaptic plasticity and memory. Dulaglutide, a blood–brain barrier (BBB)‐permeant glucagon‐like...
-
Implementation and outcomes of a statewide ECHO tele‐mentoring program to enhance dementia care in primary care settings: The Tennessee Dementia ECHO Program
Abstract BACKGROUND Primary care clinicians play a leading role in dementia care but often report limited training and confidence, particularly in rural settings. Scalable strategies are needed to strengthen workforce capacity. METHODS...
-
A Phase 2a randomized trial of once‐ versus twice‐daily remote ischemic conditioning in vascular cognitive impairment (TRIC‐VCI)
Abstract INTRODUCTION Cerebral small vessel disease.(CSVD) is a leading cause of vascular cognitive impairment.(VCI). Remote ischemic conditioning (RIC) is a promising strategy to prevent CSVD progression, but it is unclear what doses...
-
Integration of blood‐based biomarkers and genomic variants identifies individuals with mild cognitive impairment who benefit from multidomain intervention
Abstract INTRODUCTION Our recent Japan‐Multimodal Intervention Trial for the Prevention of Dementia (J‐MINT) trial suggested that multidomain lifestyle interventions may delay cognitive decline. However, substantial interindividual...
-
GLP‐1 receptor agonists in Alzheimer's disease and MCI: a meta‐analysis
Abstract INTRODUCTION Alzheimer's disease (AD) is the leading cause of dementia in older individuals and remains a major clinical and socioeconomic burden. Despite the success of anti‐amyloid therapies in reducing biomarker burden, more...
-
Therapeutic intervention strategies in frontotemporal dementia: drug development pipeline
Abstract Frontotemporal dementia (FTD) is the second most common cause of early‐onset dementia after Alzheimer's disease, characterized by substantial genetic, clinical, and pathological heterogeneity. Despite progress in understanding...
-
Advancing therapeutic approaches for agitation: A neurorelational perspective
Abstract Agitation is a common, distressing, and difficult‐to‐treat symptom in dementia, linked to emotional dysregulation and interpersonal stress. Degenerative and compensatory changes in the locus coeruleus–noradrenergic (LC–NA)...
-
How should the results of Alzheimer's disease treatment trials be communicated to colleagues, patients, and families?
Abstract The approval of amyloid‐lowering therapies for Alzheimer's disease (AD) has increased the importance of clearly and precisely communicating complex clinical trial findings to patients, caregivers, clinicians, and the wider...
-
Frontotemporal lobar degeneration therapeutic development pipeline: 2026
Abstract INTRODUCTION Frontotemporal lobar degeneration (FTLD) comprises a group of neuropathological entities underlying a spectrum of clinical syndromes, including behavioral variant frontotemporal dementia, the primary progressive...
- Electroencephalographic complexity and cognitive decline: Insights from approximate entropy across aging and dementia
- Issue Information
- Physical activity and combinations with modifiable factors and risk of cognitive impairment: the Whitehall II study